Open AccessAlefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients
Author(s) -
Mark Rigby,
Kristina M. Harris,
Ashley Pinckney,
Linda A. DiMeglio,
Marc Rendell,
Eric I. Felner,
Jean M. Dostou,
Stephen E. Gitelman,
Kurt Griffin,
Eva Tsalikian,
Peter A. Gottlieb,
Carla J. Greenbaum,
Nicole Sherry,
Wayne V. Moore,
Roshanak Monzavi,
Steven M. Willi,
Philip Raskin,
Lynette Keyes-Elstein,
S. Alice Long,
Sai Kanaparthi,
Noha Lim,
Deborah Phippard,
Carol L. Soppe,
Margret L. Fitzgibbon,
James O McNamara,
Gerald T. Nepom,
Mario R. Ehlers
Publication year - 2015
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/0rtj-8b69
Subject(s) - type 2 diabetes , medicine , diabetes mellitus , type 1 diabetes , immunology , endocrinology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom